CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
C16G2 Strip +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03052842
NCT03052842Phase 2Completed
CompareCT.gov

A Phase 2, Single-blind, Randomized, Placebo-controlled Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Strip Administered in Multiple Doses to Adolescent and Adult Dental Subjects

Armata Pharmaceuticals, Inc.·interventional·Posted Feb 14, 2017·Updated Dec 22, 2022

In Brief

A Phase 2 clinical trial evaluating C16G2 Strip and Placebo Strip for Dental Caries. Completed, enrolled 30 participants across 3 sites.

Detailed Summary

Single-blind study to evaluate whether C16G2 Strip administered in multiple doses can effectively kill the bacteria in the oral cavity that cause dental caries..

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDental Caries
CountriesUnited States
CollaboratorsVantage Data Designs, Inc., E Squared Trials and Registries, Inc., Agility Clinical, Inc.

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 14, 2017
Enrollment StartFeb 9, 2017
Primary CompletionApr 5, 2017
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 9.4 years ago

Interventions

C16G2 Stripdrug

Antimicrobial Peptide

Placebo Stripother

Placebo